News | Prostate Cancer | October 03, 2017

Immune Response Prognostic for Prostate Cancer Survival, Recurrence and Radiotherapy Response

Findings indicate new avenue for personalized medicine and potentially inform use of immunotherapy treatments currently on the market for localized prostate cancer

Immune Response Prognostic for Prostate Cancer Survival, Recurrence and Radiotherapy Response

October 3, 2017 — A new study finds that immune response in prostate cancer may be able to forecast how patients will respond to radiation therapy, as well as their likelihood of disease recurrence and survival outcomes. The analysis of more than 9,000 prostate tumors also found evidence that PD-L2, not PD-L1, may provide a key route for targeted therapies, such as immunotherapy, to slow disease progression. Findings were presented at the 59th Annual Meeting of the American Society for Radiation Oncology (ASTRO), Sept. 24-27 in San Diego.

“When the immune system responds to tumors, it sends specific types of immune cells directly to the tumor. Understanding this infiltration of immune cells allows researchers and oncologists to devise treatment strategies based on each patient’s specific immune response and disease biology. Checkpoint inhibitors and other immunotherapies have been utilized to manage other solid tumors. Our work suggests that there may be a role for these innovative treatments in prostate cancer, as well,” said Shuang (George) Zhao, M.D., lead author of the clinical study and a radiation oncology resident at the University of Michigan in Ann Arbor.

To better define the immune landscape of localized prostate cancer, researchers examined 9,393 tumor samples from men who underwent a radical prostatectomy, including 7,826 recently collected prospective tumor samples and 1,567 retrospectively obtained samples. Immune content in the tumor samples was identified using high-throughput computational analysis with specific immune-related genes. Gene expression profiling was conducted on a commercial clinical-grade platform, and gene selection was guided by the published literature.

Clustering analysis of the 9,393 tissue samples identified a subset of patients with higher expression of immune-related pathways. This immune content score, which was predicted computationally, appeared to predict prostate cancer recurrence, metastasis and survival. Higher levels of the immune content score were associated with lower likelihood of survival, including freedom from disease progression (Hazard Ratio (HR) = 1.3, p = 0.0002), freedom from distant metastases (HR = 1.3, p = 0.0006), prostate cancer-specific survival (HR = 1.5, p = 0.0003) and overall survival (HR = 1.3, p = 0.006). Clinical outcomes were available for retrospective data only.

The immune content score also predicted response to radiation therapy following radical prostatectomy. On multivariate analysis, it interacted significantly (p = 0.017) with response to post-operative radiation therapy (PORT).

“Our analyses also found a potential interaction between immune content and radiation response, suggesting that combinations of radiation therapy and immunotherapies may be a treatment option worthy of further investigation,” said Zhao.

Different types of immune cells were influential in different ways, indicating a complex interaction between immune cells and tumor cells. Specifically, higher levels of active macrophages and T-cells were prognostic for worse distant metastasis-free survival (p < 0.05), while active mast cells, NK cells and dendritic cells were associated with improved distant metastasis-free survival (p < 0.05). Individual cell types were examined from the genome-wide expression data using the CIBERSORT algorithm.

PD-L1, the target of several U.S. Food and Drug Administration (FDA)-approved checkpoint inhibitors, was not associated with outcomes in this study, but PD-L2, which interacts with PD-1 similarly to PD-L1, was associated with worse treatment outcomes. Specifically, higher levels of PD-L2 were associated with greater likelihood for disease recurrence (HR = 1.17, p = 0.013), distant metastasis (HR = 1.25, p = 0.014) and prostate cancer death (HR = 1.45, p = 0.003).

“As immune checkpoint blockers have come to market, PD-L1 has received a great deal of attention — but it does not appear to be widely expressed in prostate cancer. PD-L2, however, was much more highly expressed in these tumor samples, and it also was associated with worse outcomes. The understudied PD-L2 ligand may be the better therapeutic target for patients with localized prostate cancer,” said Zhao.

“The immune landscape of prostate cancer is highly complex. We need to develop treatment approaches that account for individual tumor and patient characteristics in order to prescribe the best treatments for each individual prostate cancer patient,” he concluded.

For more information: www.astro.org

Related Content

Clinical Trials and Cutting-Edge Radiation Oncology Research to Be Featured at ASTRO 2017

Related Content

Ultrasound-guided carpal tunnel release quickly improves hand function and reduces hand discomfort, making the procedure a safe, effective, and less invasive alternative to traditional open or endoscopic surgery

Patients answered three questionnaires (Quick-Disabilities of the Arm, Shoulder, and Hand [QDASH] and two parts of the Boston Carpal Tunnel Syndrome Questionnaire: symptom severity [BCTSQ-SS] and functional status [BCTSQ-FS] scales) assessing the affected wrist's function and discomfort immediately pre-procedure, 2 weeks post-procedure, and at least one year post-procedure. Infographic courtesy of the American Roentgen Ray Society (ARRS), American Journal of Roentgenology (AJR)

News | Ultrasound Imaging | September 17, 2020
September 17, 2020 — According to ARRS' American Journal of Roentgenology (AJR),...
Data from latest research presented at the ESMO Virtual Congress 2020 suggests COVID-19 pandemic halts cancer care and damages oncologists' wellbeing

Getty Images

News | Coronavirus (COVID-19) | September 17, 2020
September 17, 2020 — Delays and cancellation of cancer treatments and other safety measures undertaken to minimize th
Varian Drives Next Evolution of Proton Treatment Planning with Eclipse v16.1
News | Treatment Planning | September 15, 2020
September 15, 2020 — Varian announced it has received FDA 510(k) clearance for its Eclipse v16.1 treatment planning s
HABLE study prioritizes brain imaging and biomarker research among Mexican Americans.

Getty Images

News | PET Imaging | September 14, 2020
September 14, 2020 — To meet the pressing need to better understand the prevalence, progression, and clinical impact
Six months after deployment, the no-show rate of the predictive model was 15.9%, compared with 19.3% in the preceding 12-month preintervention period — corresponding to a 17.2% improvement from the baseline no-show rate (p < 0.0001). The no-show rates of contactable and noncontactable patients in the group at high risk of appointment no-shows as predicted by the model were 17.5% and 40.3%, respectively (p < 0.0001).

Weekly outpatient MRI appointment no-show rates for 1 year before (19.3%) and 6 months after (15.9%) implementation of intervention measures in March 2019, as guided by XGBoost prediction model. Squares denote data points. Courtesy of the  American Roentgen Ray Society (ARRS), American Journal of Roentgenology (AJR)

News | Artificial Intelligence | September 10, 2020
September 10, 2020 — According to ARRS’
UT Dallas study aims to advance thermography for monitoring tumors

Adolfo Lozano, PhD'20, works on a proof-of-concept computer model of the thermal properties of breast cancer. He and other UT Dallas researchers aim to improve digital thermal imaging as a tool for monitoring cancer and its treatment. Image courtesy of The University of Texas at Dallas

News | Breast Imaging | September 09, 2020
September 9, 2020 — ...
High-intensity focused ultrasound (HIFU), a technology used to treat localized prostate cancer, has shown adequate control of prostate cancer while avoiding major side effects of surgery or radiation therapy, according to a new study in The Journal of Urology, Official Journal of the American Urological Association

Getty Images

News | Prostate Cancer | September 08, 2020
September 8, 2020 — Approved by the US Food and Drug Administration (FDA) in 2015 for prostate tissue ablation, the h
A researcher holds a flexible X-ray scintillator developed by Professor Biwu Ma and his research team. The team has developed a new material that could be used to make flexible X-ray detectors that are less harmful to the environment and cost less than existing technologies. Photo courtesy of Biwu Ma / Florida State University

A researcher holds a flexible X-ray scintillator developed by Professor Biwu Ma and his research team. The team has developed a new material that could be used to make flexible X-ray detectors that are less harmful to the environment and cost less than existing technologies. Photo courtesy of Biwu Ma / Florida State University

News | X-Ray | September 03, 2020
September 3, 2020 — Florida State Univer...
the Contrast Media Injectors Market is estimated to be USD 1.3 billion in 2020 and  projected to reach $1.9B by 2025, at a CAGR of 7.4% between 2020 and 2025

Getty Images

News | Contrast Media Injectors | September 02, 2020
September 2, 2020 — According to the new market research report "...
B, Representative computational model shows lung stroma intraorgan structure of XCAT phantom that was developed using anatomically informed mathematic model. Inset shows enlarged view for better visibility of details and small structures. C, Voxelized rendition (ground truth) of XCAT phantom highlights detailed model of lung parenchyma. Inset shows enlarged view for better visibility of details and small structures

B, Representative computational model shows lung stroma intraorgan structure of XCAT phantom that was developed using anatomically informed mathematic model. Inset shows enlarged view for better visibility of details and small structures. C, Voxelized rendition (ground truth) of XCAT phantom highlights detailed model of lung parenchyma. Inset shows enlarged view for better visibility of details and small structures. Image courtesy of the American Roentgen Ray Society (ARRS), American Journal of Roentgenology (AJR)

News | Coronavirus (COVID-19) | August 26, 2020
August 26, 2020 — An...